

12<sup>th</sup> November, 2025

To

BSE Limited  
Corporate Relationship Department  
P J Towers  
Dalal Street, Fort  
Mumbai – 400 001.

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting held on 12<sup>th</sup> November, 2025

**Ref:** Security Code: 524520; Security ID: KMCSHIL

In terms of the provisions of Regulation 30 (read with Part A of Schedule III) and Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors at their meeting held today, 12<sup>th</sup> November, 2025, have inter-alia, approved the Standalone Unaudited Financial results for the quarter and half year ended 30<sup>th</sup> September, 2025 along with the Limited Review Report of the Statutory Auditors, copy of which is enclosed for your records.

We hereby inform you that the Board Meeting commenced at 10:30AM and concluded at 11:05AM.

Thank You

With regards,

For **KMC SPECIALITY HOSPITALS (INDIA) LIMITED**

**Dr S Manivannan**  
Managing Director  
DIN: 00910804



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF KMC SPECIALITY HOSPITALS (INDIA) LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMC Speciality Hospitals (India) Limited** ("the Company"), for the quarter and six months ended September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)

*Rekha Bai*

**Rekha Bai**  
(Partner)

(Membership No. 214161)  
(UDIN: 25214161BMIQOZ5039)



Place: Chennai  
Date: November 12, 2025

Statement of unaudited financial results for the quarter and six months ended September 30, 2025

(Rs. in Lakhs except EPS)

Particulars	Quarter ended			Six months ended		Year ended
	September 30, 2025 (Unaudited)	June 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2025 (Audited)
<b>1 Income</b>						
a) Revenue from operations	7,490.19	6,655.29	5,623.07	14,145.48	10,929.87	23,159.76
b) Other income	124.42	80.05	45.91	204.47	108.00	308.64
<b>Total Income</b>	<b>7,614.61</b>	<b>6,735.34</b>	<b>5,668.98</b>	<b>14,349.95</b>	<b>11,037.87</b>	<b>23,468.40</b>
<b>2 Expenses</b>						
a) Cost of materials consumed	359.42	322.95	247.62	682.37	431.72	991.15
b) Purchase of stock-in-trade	744.84	671.30	568.65	1,416.14	1,155.92	2,453.14
c) Changes in inventories of stock-in-trade	(0.66)	41.74	(4.27)	41.08	(48.73)	(76.64)
d) Employee benefits expense	1,695.18	1,531.83	1,299.07	3,227.01	2,555.52	5,189.02
e) Finance costs	204.52	216.43	269.33	420.95	477.36	941.59
f) Depreciation and amortisation expense	530.42	508.22	495.24	1,038.64	903.24	1,895.25
g) Other expenses	2,606.94	2,442.25	2,259.83	5,049.19	4,289.66	8,914.55
<b>Total expenses</b>	<b>6,140.66</b>	<b>5,734.72</b>	<b>5,135.47</b>	<b>11,875.38</b>	<b>9,764.69</b>	<b>20,308.06</b>
<b>3 Profit before tax (1-2)</b>	<b>1,473.95</b>	<b>1,000.62</b>	<b>533.51</b>	<b>2,474.57</b>	<b>1,273.18</b>	<b>3,160.34</b>
<b>4 Income tax expense</b>						
a) Current tax (Including prior years)	337.46	308.53	163.41	645.99	294.08	730.79
b) Deferred tax	52.38	(61.42)	(18.31)	(9.04)	39.97	286.84
<b>Total income tax expense</b>	<b>389.84</b>	<b>247.11</b>	<b>145.10</b>	<b>636.95</b>	<b>334.05</b>	<b>1,017.63</b>
<b>5 Profit for the period (3-4)</b>	<b>1,084.11</b>	<b>753.51</b>	<b>388.41</b>	<b>1,837.62</b>	<b>939.13</b>	<b>2,142.71</b>
<b>6 Other comprehensive loss</b>						
Items that will not be reclassified subsequently to profit or loss						
(a) Re-measurement of defined benefit plans (net)	(42.28)	(22.58)	(1.85)	(64.86)	(11.93)	(90.32)
(b) Income tax relating to items that will not be reclassified to profit or loss	10.65	5.68	0.46	16.33	3.00	22.73
<b>Total other comprehensive loss, net of tax</b>	<b>(31.63)</b>	<b>(16.90)</b>	<b>(1.39)</b>	<b>(48.53)</b>	<b>(8.93)</b>	<b>(67.59)</b>
<b>7 Total comprehensive income (5+6)</b>	<b>1,052.48</b>	<b>736.61</b>	<b>387.02</b>	<b>1,789.09</b>	<b>930.20</b>	<b>2,075.12</b>
<b>8 Paid-up equity share capital (Face value of Re.1/- each)</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>
<b>9 Other equity</b>						<b>14,802.24</b>
<b>10 Earnings per share (EPS) of Re. 1/- each :</b>						
Basic	0.66	0.46	0.24	1.13	0.58	1.31
Diluted	0.66	0.46	0.24	1.13	0.58	1.31
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)



Statement of assets and liabilities

		(Rs. in Lakhs)	
	Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
<b>A</b>	<b>Assets</b>		
<b>1</b>	<b>Non-current assets</b>		
(a)	Property, plant and equipment	23,473.64	23,968.63
(b)	Right-of-use assets	965.65	756.26
(c)	Investment property	40.43	40.43
(d)	Other intangible assets	3.82	4.41
(e)	Financial assets		
	(i) Investments	0.72	0.38
	(ii) Other financial assets	268.96	250.70
(f)	Income tax assets (net)	82.29	238.46
(g)	Other non-current assets	122.09	16.45
	<b>Sub-total - Non-current assets</b>	<b>24,957.60</b>	<b>25,275.72</b>
<b>2</b>	<b>Current assets</b>		
(a)	Inventories	309.45	350.21
(b)	Financial assets		
	(i) Trade receivables	709.21	597.85
	(ii) Cash and cash equivalents	2,387.71	919.04
	(iii) Bank balances other than (ii) above	588.05	15.06
	(iv) Loans	35.70	25.97
	(v) Other financial assets	789.92	1,263.70
(c)	Other current assets	180.03	152.31
	<b>Sub-total - Current assets</b>	<b>5,000.07</b>	<b>3,324.14</b>
	<b>Total - Assets</b>	<b>29,957.67</b>	<b>28,599.86</b>
	<b>Equity and liabilities</b>		
<b>1</b>	<b>Equity</b>		
(a)	Equity share capital	1,630.85	1,630.85
(b)	Other equity	16,591.33	14,802.24
	<b>Sub-total - Equity</b>	<b>18,222.18</b>	<b>16,433.09</b>
<b>2</b>	<b>Non-current liabilities</b>		
(a)	Financial Liabilities		
	(i) Borrowings	6,686.39	7,232.67
	(ii) Lease Liabilities	702.91	552.09
(b)	Provisions	368.43	249.69
(c)	Deferred tax liabilities (net)	302.54	327.90
(d)	Other non-current liabilities	10.51	10.36
	<b>Sub-total - Non-current liabilities</b>	<b>8,070.78</b>	<b>8,372.71</b>
<b>3</b>	<b>Current liabilities</b>		
(a)	Financial liabilities		
	(i) Borrowings	960.00	960.00
	(ii) Lease liabilities	268.93	199.99
	(iii) Trade payables		
	(A) Total outstanding dues of micro enterprises and small enterprises	79.08	246.16
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	923.58	1,162.18
	(iv) Other financial liabilities	552.78	558.27
(b)	Other current liabilities	504.10	421.31
(c)	Provisions	376.24	246.15
	<b>Sub-total - Current liabilities</b>	<b>3,664.71</b>	<b>3,794.06</b>
	<b>Sub-total - Liabilities</b>	<b>11,735.49</b>	<b>12,166.77</b>
	<b>Total - Equity and liabilities</b>	<b>29,957.67</b>	<b>28,599.86</b>



**Statement of unaudited cash flow statement**


Particulars	For the six months ended September 30, 2025 (Unaudited)	For the six months ended September 30, 2024 (Unaudited)
<b>A Cash flows from operating activities</b>		
Profit before tax	2,474.57	1,273.18
Adjustments:		
Depreciation and amortisation expense	1,038.64	903.24
Provision for loss allowance	18.55	19.99
Rental Income	(9.67)	(10.81)
Finance costs	420.95	477.36
Interest income from banks	(59.58)	(41.01)
Interest income from others	(3.90)	(3.23)
<b>Operating profit before working capital / other changes</b>	<b>3,879.56</b>	<b>2,618.72</b>
Adjustment for (increase)/decrease in operating assets		
Inventories	40.76	(119.29)
Trade receivables	(129.91)	(235.94)
Other financial assets and other assets - Non-current	(32.92)	(37.75)
Other financial assets and other assets - Current	(72.54)	(213.29)
Adjustment for increase/(decrease) in operating liabilities		
Trade payables	(405.69)	599.23
Liabilities and provisions	278.24	178.61
<b>Cash generated from operations</b>	<b>3,557.50</b>	<b>2,790.29</b>
Direct taxes paid (net)	(489.82)	(423.06)
<b>Net cash flow from operating activities (A)</b>	<b>3,067.68</b>	<b>2,367.23</b>
<b>B Cash flows from investing activities</b>		
Acquisition of property, plant and equipment (Including capital advances, net of capital creditors)	(563.49)	(4,429.66)
Investment made during the period	(0.34)	-
(Investment made)/redemption of bank deposits (net)	(19.24)	1,237.19
Rent received	9.67	10.81
Interest received	23.93	52.50
<b>Net cash used in investing activities (B)</b>	<b>(549.47)</b>	<b>(3,129.16)</b>
<b>C Cash flows from financing activities</b>		
Proceeds from non-current borrowings	-	1,565.38
Repayment of non-current borrowings	(546.28)	(473.07)
Payment of lease liabilities	(123.14)	(129.42)
Interest and finance charges paid	(380.12)	(428.97)
<b>Net cash (used in) / from financing activities (C)</b>	<b>(1,049.54)</b>	<b>533.92</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>1,468.67</b>	<b>(228.01)</b>
Cash and cash equivalents at the beginning of the period	919.04	484.57
<b>Cash and cash equivalents at the end of the year</b>	<b>2,387.71</b>	<b>256.56</b>
<b>Components of cash and cash equivalents:</b>		
Cash on hand	25.46	25.05
Balances with banks		
- on current accounts	330.25	231.51
- on deposit accounts (original maturity of three months or less)	2,032.00	-
	<b>2,387.71</b>	<b>256.56</b>



**Notes:**

- 1 These above unaudited financial results of KMC Speciality Hospitals (India) Limited ("the Company") for the quarter and six months ended September 30, 2025 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 2 The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on November 11, 2025 and November 12, 2025, respectively. The results for the quarter and six months ended September 30, 2025 has been reviewed by our statutory auditors. The statutory auditors have issued an unmodified review report for the quarter and six months ended September 30, 2025.
- 3 The Company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under IND AS 108 - "Operating Segments".

Place: Chennai  
Date: November 12, 2025



for and on behalf of the board of directors of  
KMC Speciality Hospitals (India) Limited  
CIN: L85110TN1982PLC009781

Dr. S. Manivannan  
Managing Director  
DIN: 00910804